Dopamine-induced apoptosis in human neuronal cells: Inhibition by nucleic acids antisense to the dopamine transporter

Neuroscience

Volumn 74, Issue 1, 1996, Pages 39-50

  Simantov, R ^a   Blinder, E ^a   Ratovitski, T ^a   Tauber, M ^a   Gabbay, M ^a   Porat, S ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

cell death; neurodegeneration; Parkinson's disease; transporter

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARRIER PROTEIN; COCAINE; COMPLEMENTARY DNA; CYCLOHEXIMIDE; DESIPRAMINE; DNA FRAGMENT; DOPAMINE; IMIPRAMINE; LACTATE DEHYDROGENASE; NORADRENALIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OXIDOPAMINE; SEROTONIN UPTAKE INHIBITOR; SYNTHETIC PEPTIDE;

ARTICLE; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINE UPTAKE; DOSE TIME EFFECT RELATION; ENZYME RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROTOXICITY; PRIORITY JOURNAL; TRANSPORT KINETICS;

EID: 0029761452     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(96)00102-9     Document Type: Article

References (59)

1. Akhtar S. and Juliano R. L. (1992) Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 2, 139-144.
2. Bannon M. J., Poosch M. S., Xia Y., Goebel D. J., Cassin B. and Kapatos G. (1992) Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. natn. Acad. Sci. U.S.A. 89, 7095-7099.
3. Bloom F. E., Algeria S., Proppetti A., Revuelta A. and Costa E. (1969) Lesions of central norepinephrine terminals with 6-hydroxydopamine: biochemistry and fine structure. Science 166, 1284-1286.
4. Brodeur G. M., Sekhon G. S. and Goldstein M. N. (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40, 2256-2263.
5. Burns R. S., Chiueh C. C., Markey S. P., Herbert M. H., Jacobowitz D. M. and Kopin I. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80, 4546-4550.
6. Bursch W., Oberhammer F. and Schulte-Hermann R. (1992) Cell death by apoptosis and its protective role against disease. Trends pharmac. Sci. 13, 245-251.
7. Calne D. and Langsten J. W. (1983) Eulogy of Parkinson's disease. Lancet 2, 1457-1459.
8. Carlsson A. and Winblad B. (1976) Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J. neural Transm. 38, 271-276.
9. Carlsson M. and Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
10. Cohen J. J. and Duke R. C. (1984) Glucocorticoid activation of calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immun. 132, 38-42.
11. Cowan W. M., Fawcett J. W., O'Leary D. D. M. and Stanfield B. B. (1984) Regressive events in neurogenesis. Science 255, 1258-1265.
12. Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
13. Coyle J. T. and Snyder S. H. (1969) Catecholamine uptake by synaptosomes in homogenates of rat brain : stereospecificity in different area. J. Pharmac. exp. Ther. 170, 221-231.
14. Davies A. M. (1994) Intrinsic programmes of growth and survical in developing vertebrate neurons. Trends Neurosci. 17, 195-199.
15. Deckwerth T. L. and Johnson E. M. Jr (1993) Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J. Cell Biol. 123, 1207-1222.
16. De Keyser J., Ebinger G. and Vauguelin G. (1990) Age-related changes in the human nigrostriatal dopaminergic system. Ann. Neural. 21, 157-161.
17. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P. and Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkonson's disease. J. Neurochem. 52, 381-389.
18. Di Monte D. and Smith M. T. (1988) Free radicals, lipid oxidation and l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) -induced Parkinsonism. A. Rev. Neurosci. 2, 67-81.
19. Freeman R. S., Estus S. and Johnson E. M. Jr (1994) Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin D1 during programmed cell death. Neuron 12, 343-355.
20. Gerlach M., Riederer P., Przuntek H. and Youdim M. B. H. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmac. 208, 273-286.
21. Giros, B., El Mestikawy S., Bertrand L. and Caron M. G. (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. Fed Eur. biochem. Socs Lett. 295, 149-154.
22. Giros B., El Mestikaway S., Godinot N., Zheng K., Han H., Yang-Feng T. and Caron M. G. (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molec Pharmac. 42, 283-290.
23. Graham D. G. (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5, 83-96.
24. Graybiel A. M. (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13, 244-254.
25. Heikkila R. E., Hess A. and Duvoisin R. V. (1984) Dopaminergic neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224, 1451-1453.
26. Hirsch E. C., Graybiel A. M. and Agid Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 245-248.
27. Hornykiewicz O. (1973) Parkinson's disease: from brain homogenate to treatment. Fedn Proc. 32, 183-190.
28. Javitch J. A., D'Amato R. J., Strittmatter S. M. and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-niethyl-4-phenyl-l,2,3.6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. natn Acad. Sci. U.S.A. 82, 2173-2177.
29. Kerr J. F. R., Searle J., Harmon B. M. and Bishop C. J. (1987) Apoptosis. In Prospectives on Mammalian Cell Death (ed. Potten C. S.), pp. 93-119. Oxford University Press, Oxford.
30. Kessler J. A., Ludlam W. H., Freidin M. M., Hall D. H., Michaelson M. D., Spray D. C., Dougherty M. and Batter D. K. (1993) Cytokine-induced programmed death of cultured sympathetic neurons. Neuron 11, 1123-1132.
31. Kilty J. E., Lorang D. and Amara S. G. (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254, 578-579.
32. Kish S. J., Morito C. L. H. and Hornykiewicz O. (1986) Brain glutathione peroxidase in neurodegenerative disorders. Neurochem. Path. 4, 23-28.
33. Krueger B. K. (1990) Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 55, 260-267.
34. Langsten L. W., Ballard P., Tetrud J. W. and Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
35. + +-independent dopamine release from striatal slices: a possible role of reverse dopamine transport. J. Pharmac. exp. Ther. 256, 1132-1138.
36. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265-275.
37. Macaya A., Munell F., Gubits R. M. and Burke R. E. (1994) Apoptosis in substantia nigra following developmental striatal excitotoxic injury. Proc. natn. Acad. Sci. U.S.A. 91, 8117-8121.
38. Marshall J. F., O'Dell J. J., Navarrete R. and Rosenstein A. J. (1990) Dopamine high affinity transport site topography in rat brain: major differences between dorsal and ventral striatum. Neuroscience 37, 11-21.
39. McGeer P. L. McGeer E. G. and Suzuki J. S. (1977) Aging and extrapyramidal function. Archs Neurol. 34, 33-35.
40. Olanow C. W. (1993) A radical hypothesis for neurodegeneration. Trends Nuerosci. 16, 439-444.
41. Oltvai Z., Milliman C. and Korsmeyer S. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619.
42. Oppenheim R. W. (1991) Cell death during development of the nervous system. A Rev. Neurosci. 14, 453-501.
43. Pacholczyk T. R., Blakely R. and Amara S. G. (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350, 350-354.
44. Perry T. L., Godin D. V. and Hensen S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci. Lett. 33, 305-310.
45. Price J., Turner D. and Cepko C. (1987) Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc. natn. Acad. Sci. U.S.A. 84, 156-160.
46. Rosenberg E., Linder-Eliasson E. and Carlsson A. (1985) Detection of 5-S-cysteinyldopamine in human brain. J. neural Transm. 63, 247-253.
47. Seeman P. and Niznik H. B. (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. Fedn Proc. Fedn Am. Socs. Exp. Biol. 4, 2737-2744.
48. Shimada S., Kitayama S., Lin C.-L., Patel A., Nanthakuram E., Gregor P., Kuhar M. K. and Uhl G. (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254, 576-578.
49. Sivam S. P., Krause J. E., Breese G. R. and Hong J.-S. (1991) Dopamine-dependent postnatal development of enkephalin and tachykinin neurons of rat basal ganglia. J. Neurochem. 56, 1499-1508.
50. Slivka A. and Cohen G. (1985) Hydroxyl radical attack on dopamine. J. biol. Chem. 260, 15466-15472.
51. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
52. Ungerstedt U. (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmac. 5, 107-110.
53. Uretsky N. J. and Iversen L. L. (1970) Effects of 6-hydroxydopamine on catecholamine containing neurons in rat brain. J. Neurochem. 17, 269-278.
54. Usdin T. B., Mezey E., Brownstein M. J. and Huffman B. J. (1991) Cloning of the cocaine-sensitive bovine dopamine transporter. Proc. natn. Acad. Sci. U.S.A. 88, 11168-11171.
55. Wahlestedt C. (1994) Antisense oligonucleotide strategies in neuropharmacology. Trends pharmac. Sci. 15, 42-46.
56. Youdim M. B. H., Ben-Shachar D. and Riederer P. (1993) The possible role of iron in the etiopathology of Parkinson's disease. Movement Disorders 8, 1-12.
57. Youdim M. B. H. and Riederer P. (1993) Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J. neural Transm. 91, 181-195.
58. Zigmond M. J., Hastings T. G. and Abercrombie E. D. (1992) Neurochemical responses to 6-hydroxydopamine and L-Dopa therapy: implications for Parkinson's disease. Ann. N. Y. Acad. Sci. 648, 71-85.
59. Ziv. I., Melamed E., Nardi N., Luria D., Achiron A., Offen D. and Barzilai A. (1994) Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170, 136-140.